Chugai Pharmaceutical Co., Ltd. CHGCY · Stock Open Chugai Pharmaceutical Co., Ltd. in new tab
Chugai Pharmaceutical Co., Ltd. Analysis (CHGCY)
Is Chugai Pharmaceutical Co., Ltd. a good investment? Chugai Pharmaceutical Co., Ltd. (CHGCY) is currently trading at 21.50 USD.
In terms of valuation, the stock trades at a P/E ratio of 23.03. This valuation is generally in line with the broader market.
Earnings Schedule: Chugai Pharmaceutical Co., Ltd. is expected to release its next earnings report on Oct. 23, 2026.
For income investors, Chugai Pharmaceutical Co., Ltd. pays a dividend yield of 3.16%. With a payout ratio of 95%, the dividend appears to be under pressure.
Investor FAQ
Does Chugai Pharmaceutical Co., Ltd. pay a dividend?
Yes, it pays an annual dividend of 106.50 USD (3.16% yield).
What asset class is Chugai Pharmaceutical Co., Ltd.?
Chugai Pharmaceutical Co., Ltd. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Oct. 23, 2026. The company currently has a trailing EPS of 0.93.
Company Profile
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Lunsumio, Perjeta, Phesgo, Polivy, and Tecentriq; Actemra for humanized anti-human IL-6 receptor monoclonal antibody; CellCept, an immunosuppressant; Enspryng, a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody; Evrysdi, a spinal muscular atrophy agent; Hemlibra, an anti-coagulation factor IXa/X humanized bispecific monoclonal antibody; Mircera, an erythropoiesis-stimulating agent; PiaSky, a pH-dependent binding humanized anti-complement (C5) monoclonal antibody; Tamiflu, an anti-influenza agent; and Vabysmo, an anti VEGF/anti Ang-2 bispecific antibody. The company has a collaboration with Phylo, Inc. to deploy an agentic AI platform for biomedical research across its drug discovery workflow. The company was formerly known as Chugai Shinyaku Shokai and changed its name to Chugai Pharmaceutical Co., Ltd. in January 1943. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding AG.
| Year | Total Dividends |
|---|---|
| ▸2027 |
0.67 USD
|
| April 14, 2027 (estimated) | 0.4665 |
| March 29, 2027 | 0.2079 |
| ▸2026 |
0.64 USD
|
| Sept. 14, 2026 | 0.1760 |
| April 10, 2026 | 0.4599 |
| ▸2025 |
0.61 USD
|
| Sept. 12, 2025 | 0.4252 |
| April 11, 2025 | 0.1890 |
| ▸2024 |
0.25 USD
|
| Sept. 13, 2024 | 0.1150 |
| April 1, 2024 | 0.1322 |
| ▸2023 |
0.29 USD
|
| Sept. 14, 2023 | 0.1373 |
| April 14, 2023 | 0.1504 |
| ▸2022 |
0.33 USD
|
| Sept. 14, 2022 | 0.1369 |
| April 14, 2022 | 0.1887 |
| ▸2021 |
0.27 USD
|
| Sept. 14, 2021 | 0.1365 |
| April 7, 2021 | 0.1380 |
| ▸2020 |
3.13 USD
|
| Sept. 14, 2020 | 1.4231 |
| April 15, 2020 | 1.7105 |
| ▸2019 |
1.90 USD
|
| Sept. 16, 2019 | 0.9046 |
| April 15, 2019 | 0.9929 |
| ▸2018 |
1.19 USD
|
| Sept. 17, 2018 | 0.5592 |
| April 9, 2018 | 0.6290 |
| ▸2017 |
0.53 USD
|
| Sept. 18, 2017 | 0.5267 |
| ▸2016 |
1.54 USD
|
| Dec. 28, 2016 | 0.4691 |
| Sept. 19, 2016 | 0.5004 |
| April 8, 2016 | 0.5658 |
| ▸2015 |
0.43 USD
|
| June 25, 2015 | 0.4339 |
| ▸2014 |
10.27 USD
|
| Dec. 26, 2014 | 5.2376 |
| June 25, 2014 | 5.0287 |
| ▸2013 |
10.76 USD
|
| Dec. 27, 2013 | 5.3907 |
| June 25, 2013 | 5.3740 |
| ▸2012 |
8.69 USD
|
| Sept. 14, 2012 | 7.6942 |
| Sept. 14, 2012 | 0.5103 |
| April 12, 2012 | 0.4869 |
| ▸2011 |
0.52 USD
|
| Sept. 19, 2011 | 0.5194 |
| Name | Payment Date | Status | Amount |
|---|---|---|---|
| Chugai Pharmaceutical Co., Ltd. | Mar 29, 2027 | Upcoming | 0.20785 USD |
| Chugai Pharmaceutical Co., Ltd. | Sep 14, 2026 | Paid | 0.176 USD |
| Chugai Pharmaceutical Co., Ltd. | Apr 10, 2026 | Paid | 0.45985 USD |
| Split Date | Split Ratio to 1 |
|---|---|
| July 6, 2020 | 12:1 |
Community Discussion